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Summary: Data collected between 1983 and 1991 in interlaboratory surveys of the determination of tumour
markers are used to show the magnitude of the scatter of results from different laboratories for the analysis
of a single quantity in a given matrix. These data also show that the varying specificity of different reagent
combinations appears to make a considerable contribution to this scatter, and that the used reagent combi-
nations were not of uniform quality over a relatively extended period. The results for the following tumour
markers were studied: -fetoprotein (AFP), carcinoembryonic antigen (CEA), human chorionic gonadotropin
(hCG), human chorionic gonadotropin + ß-subunit (hCG + ß-hCG), tissue polypeptide antigen (TPA),
carbohydrate antigen 19-9 (CA 19-9), cancer antigen 15-3 (CA 15-3), cancer antigen 125 (CA 125), prostatic
acid phosphatase (PAP) and prostate-specific antigen (PSA).
Introduction
During the last decade, in the field of tumour diag-
nosis, many more quantitative determinations for
tumour markers have become available, and the num-
ber of these determinations requested and performed
has also markedly increased. The determination meth-
ods are based exclusively on immunochemical prin-
ciples, whose complex procedures are more subject to
systematic and random errors, compared with many
procedures of more traditional clinical chemical anal-
ysis.
Soon after the introduction of the determination of
tumour markers, the necessity arose to test the relia-
bility of the analytical results in collaborative inter-
laboratory surveys, as far as this was possible under
the preconditions laid down for such tests (1). Since
1981, regular iiiterlaboratory surveys of tumour
markers have been carried out in collaboration with
the German Society for Clinical Chemistry. The first
interlaboratory surveys were conducted on three tum-
our markers: -fetoprotein, carcinoembryonic antigen
and human chorionic gonadotropin (2). By 1991 the
number of tumour markers under survey had in-
creased to 10 and, by the end of 1991, the number of
participating laboratories to 430.
More thorough investigations were promoted by the
survey results of 1991, which revealed an especially
wide scatter for certain analytical quantities.
The way in which the concept of the surveys is put
into practice provides no basis for a detailed criticism
of methods. Rather, these investigations had the fol-
lowing two-fold aim: on the one hand they sought to
establish the magnitude of the scatter of results from
different laboratories for individual tumour markers
during an extended observation period. On the other
hand, it was of interest to determine whether any
characteristic differences existed between results ob-
tained with different reagent combinations (kits). The
results from the most frequently determined tumour
markers, carcinoembryonic antigen and a-fetoprotein,
provide the most comprehensive data for the discus-
sion of this problem. It therefore seemed reasonable
to base a more detailed study on these two analytical
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quantities. In this connection, the results of surveys,
in which samples of the same material were repeatedly
analysed at different time intervals, were especially
informative.
Materials and Methods
Col labora t ive i n t e r l abo ra to ry surveys
Two pilot surveys were conducted in 1981 and 1982. Since 1983,
three interlaboralory surveys have been performed each year.
The results of the surveys from 1983 to 1991 inclusive are the
subject of the present communication. Two different samples
for the quantitative determination of tumour markers were used
in each survey. Aliquots of these samples were sent to each
participating laboratory. The results were collected and evalu-
ated by the survey management.
A n a l y t i c a l quant i t i es of the in te r l abora to ry surveys
The surveys covered the following quantitative analyses for
tumour markers: α-fetoprotein (AFP), carcinoembryonic anti-
gen (CEA), human chorionic gonadotropin (hCG), human cho-
rionic gonadotropin 4- -subunit (hCG + -hCG), tissue pol-
ypeptide antigen (TPA), carbohydrate antigen 19-9 (CA 19-9),
cancer antigen 15-3 (CA 15-3), cancer antigen 125 (CA 125),
prostatic acid phosphatase, prostate-specific antigen.
Sample mater ia l of the in ter laboratory surveys
Sample material was prepared in our own laboratory. To in-
crease the concentration of tumour markers, commercial prep-
arations and/or pooled patient sera were added to pooled
human serum. After homogenization and filtration (filter pore
size 0.2 μπα), the resulting serum was divided into aliquots of
2.5 ml, which were placed in glass vessels, lyophilized and
sealed.
Some examples of the sources of added tumour markers are:
carcinoembryonic antigen (patient serum and commercial prep-
arations from Calbiochem, PAN-Systems, and Dako Diagnos-
tic); α-feloprotein (umbilical serum); human chorionic gonad-
otropin (Boehringer Mannheim); tissue polypeptide antigen
(Sangtec), carbohydrate antigen 19-9 (patient serum), cancer
antigen 15-3 (Centocor and patient serum), cancer antigen 125
(Centocor and patient serum), prostatic acid phosphatase (pa-
tient serum and commercial preparations from Scripps Labo-
ratories), prostate-specific antigen (patient serum and commer-
cial preparations from Scripps Laboratories).
Evaluation of the interlaboratory surveys
The results of the evaluation of each analytical quantity were
presented as follows.
1. A Youden diagram with identification of all single values,
and separate labelling of the values of each participant.
2. The median and scatter (given as the 16th and 84th percen-
tiles) for the total collective of all results for each analytical
quantity.
3. The median and the 16th and 84th percentiles for each
subcollective of users of the same method or commercial
kit.
4. Graphical presentation of the data from 2. and 3. (see fig. 2).
Variabil i ty of the results for an analytical quant i ty
in a survey sample
Variability is defined here as half of the difference between the
84th and 16th percentiles (P), relatiye to the median (as a
percentage):
(84 Ρ - 16 Ρ) χ 100/(2 χ median) = variability.
Note: In the unusual event that the results are normally dis-
tributed, the median is equal to the average value, and the
variability is equal to the variation coefficient.
Calculation of the average,
concentration-dependent variability
Average scatters of the results of interlaboratory surveys can
be displayed as concentration-dependent scatter profiles (3) (see
fig. 3). For each survey collective, these profiles were con-
structed by plotting the relative differences between the median
and the respective 16th and 84th percentiles against the median.
Two hyperbolic regression curves (the scatter profiles) were
then calculated, one for the upper and the other for the lower
accumulation of points.
The variability data displayed in table 1 are based on survey
data for the years 1986 to 1991; during this time 19 different
specimens were used in the surveys. For quantities introduced
later into the survey, fewer different specimens were used, i. e.
18 each for cancer antigen 15-3 and carbohydrate antigen 19-
9, and 15 each for cancer antigen 125, prostatic acid phospha-
tase and prostate-specific antigen. The scatter profiles, from
which the data are taken, were of two types. Thus, they were
either calculated from the total collective of survey results for
each single analytical .quantity, irrespective of the analytical
method, or they were calculated from subeollectives of results
obtained with the same kit.
Selected examples
A full and detailed treatment of all the results of the relevant
interlaboratory surveys would exceed the reasonable limits of
this publication. Examples have been chosen that are represen-
tative of the present state of development of tumour diagnosis,
and for which the number of results within each collective is
sufficiently large to ensure that the resulting data will be mean-
ingful.
Def in i t i ons of terms and codes
Kit:
Subcollective:
a product from a manufacturer or supplier of
diagnostic reagents, offered commercially as
an analytical method, and consisting of the
instructions for use, the reagents and, where
applicable, the analytical apparatus. This is
the usual definition of a kit.
all the analytical results for a given analytical
quantity in a given matrix, determined with
same kit.
Total collective: all the results for a given analytical quantity
in a given matrix, irrespective of the methods
used.
Kit codes: Kits were assigned a three digit code. The last
two digits identified the manufacturer, while
the first digit indicated the analytical principle
of measurement:
1: measurement of radioactivity
2: measurement oi^enzyme activity
3: measurement of light
Kit 2 28 is therefore an enzyme-immunoassay from manufac-
turer 28.
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Accuracy
It is not possible to test the accuracy of tumour marker analyses,
because no analytical methods (e.g. reference methods) are
known for the reliable determination of the true tumour marker
concentrations. Studies must therefore be based on the detection
and evaluation of differences between individual analytical re-
sults or between groups of analytical results for analyses per-
formed on a given material.
Results and Discussion
Number of participants
Figure 1 shows the increase in the total number of
participating laboratories, as well as number of lab-
oratories analysing each of eleven analytical quanti-
ties.
The total number of participants increased from 120
in 1983 to 430 in 1991. Whereas the number of par-
ticipants for human chorionic gonadotropin (total),
prostatic acid phosphatase and tissue polypeptide an-
tigen almost stagnated, for the seven other analytes
there was an increase in the number of participating
laboratories, which was roughly parallel to the in-
crease in total participants. There was a decrease in
the number of laboratories that determined human
chorionic gonadotropin and calibrated their assay
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Fig. 1. Changes in the numbers of laboratories participating in
interlaboratory surveys from 1983 to 1991.
1 = Total number of participants,
2 = carcinoembryonic antigen,
3 = a-fetoprotein,
4 = carbohydrate antigen 19-9,
5 = prostate-specific antigen,
6 = cancer antigen 125,
7 = cancer antigen 15-3,
8 = human chorionic gonadotropin + p-subunit
(l.IRP),
9 = prostatic acid phosphatase,
10 = tissue polypeptide antigen,
11 = human chorionic gonadotropin,
12 = human chorionic gonadotropin + -subunit
(2. IS)
with the second international standard for bioassays.
Since participation is voluntary, the commitment of
most of the analysts involved is probably above av-
erage. These numbers therefore provide only a qual-
ified assessment of the overall situation. However, the
continual increase in participants certainly indicates
an increasing interest in external quality control, as
well a real increase in the number of laboratories
involved in the determination of tumour markers.
Scatter of interlaboratory survey results
In evaluating the scatter of interlaboratory survey
results, account must be taken of both internal lab-
oratory scatter, and scatter between different labo-
ratories. Internal laboratory precision depends pri-
marily on the size of unavoidable, random errors. The
scatter of results between different laboratories, as
encountered in interlaboratory surveys, is additionally
due to laboratory-specific differences in the imple-
mentation of methods, and especially to the marked
dependency of the analytical results on the kit used.
The variations caused by these two influences have
the character of systematic errors. There is, of course,
only one correct value for each analysis, but in the
present state of development of tumour marker anal-
ysis, it is not possible to determine the systematic
error for the determination of any tumour marker.
Since reliable accuracy criteria (reference method val-
ues or assigned values) are lacking, it is not possible
to determine which results are correct.
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Fig. 2. Results (pg/l) of the carcinoembryonic antigen deter-
mination in the interlaboratory survey of November
1991, subdivided according to methods and manufac-
turers, with graphical presentation of the medians (|)
and the -ranges between the 16th and 84th percentiles
N = number of participants; Min = lowest analytical
value; Max = highest analytical value; CEA = carci-
noembryonic antigen
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The graphical presentation of the medians and per-
centiles of an interlaboratory survey of the most fre-
quently investigated analytical quantity, carcinoem-
bryonic antigen (fig. 2), clearly shows that the total
scatter of the results is crucially and greatly influenced
by the position, i.e. the medians, of the individual
subcollectives.
The medians of the subcollectives sometimes show
considerable differences amongst themselves. Such
differences are largely responsible for the large scatter
of the values of the total collective (fig. 2, line "All").
The scatter of each subcollective (fig. 2, subsequent
lines) is usually relatively small.
Table 1 lists the scatter of results for ten tumour
markers, showing the values for total collectives, as
well as those for subcollectives of the most frequently
used kits. The following brief comments may be made
on the origin and significance of these values.
The average variability, as derived from each concen-
tration-dependent scatter profile, is the measure of
scatter. As an example, figure 3 shows the scatter
profile for the total collective of results for a-fetopro-
tein; the regression curves show an increase of scatter
with decreasing concentration precisely in the clini-
cally relevant decision range. To define this situation
briefly and numerically, the variability at the upper
and lower limit of a selected concentration range was
taken from the graph and listed in table 1. For the
total collective of the α-fetoprotein determination, the
variability was 24% at 6 kU/1, and 18% at 30 kU/1.
Corresponding scatter profiles were calculated for the
other tumour markers, as well as for a series of
relatively large subcollectives. Variability data were
again taken fom these profiles and listed in table 1.
20 40 60 80 100
oc-Fetoprotein [kIU/1]
120
Fig. 3. Concentration-dependent scatter profiles (d(%)) (see
Materials and Methods) for the analytical quantity oc-
fetoprotein. The variabilities at two concentrations (6
and 30 kU/1) given in table 1 are labelled. Results for
the period 1986-1991.
These variability data show
— the extent of the scatter that can be expected in
the results from different laboratories, with the
present state of development of tumour marker
analysis,
— that the scatter, both of the total collective and of
subcollectives, in most cases increased with de-
creasing analyte concentration,
— that the scatter of each subcollective, in analogy
with the example in figure 2, was usually signifi-
cantly less than in the corresponding total collec-
tive.
Kit-dependency of the results
The finding that the scatter displayed by a total col-
lective was usually larger than that of each of its
subcollectives suggested a possible causal relationship
between the kit used and the values obtained. This
was therefore subjected to a more detailed investiga-
tion, making use of available examples.
Tab. 1. Variability (see Materials and Methods) of the results of interlaboratory surveys for 10 tumour markers each of them
analysed once or twice in up to 19 different specimens. Variabilities (for the total collective and for up to four subcollectives
of laboratories using the same kit) were taken from the appropriate concentration-dependent scatter profiles (e. g. fig. 3)
at two defined concentrations.
Analyte in
serum
AFP
-CEA
hCG
hCG
-h -hCG
TPA
CA 125
CA 15-3
CA 19-9
PSA
PAP
Concentration
range of the
samples used
6-
5-
5-
134 kU/1
52 μ§/1
180 U/l
230 U/l
94-4500 U/I
8-
11-
8-
1-
1-
41 kU/1
40 kU/1
540 kU/1
12 μ§/1
21 μ§/1
Observed
cfitifpnfrit l ΙΛΤΙ
range
6- 30
5- 30
5- 30
5- 30
95-400
10- 40
13- 35
16- 50
1- 10
2.5- 20
kU/1
μg/l
u/r
U/1-
U/l
kU/1
kU/1
kU/1
μg/l
μ§/1
Variability
All
results
%
24-18
22-22
30-11
30-11
14-14
31-18
16-16
35-26
45-36
33-26
Results from users of defined kits
%
14-12
10-10
24- 7
14-14
25-12
15-15
21-14
(Kit)
(176)
(1 04)
(176)
(132)
(104)
(1 30)(104)
%
21-14
15-11
11-11
24-11
14-14
18-13
(Kit)
(204)
(204)
(204)
(130)
(132)
(130)
% (Kit)
19- 8 (228)
15- 9 (228)
24-11 (132)
14-i;4 (228)
25-21 (132)
% (Kit)
65-22 (228)
11-9 (228)
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Fig. 4. Relative differences between the medians of the results
for carcinoembryonic antigen obtained with kit 1 04
(O) or kit 1 76 (o) and the corresponding medians of
the total collectives. Intel-laboratory surveys (6 samples
per year) conducted from 1986 to 1991.
Figure 4 shows, for the analytical quantity carcinoem-
bryonic antigen, the relative deviations of the medians
of the subcollectives kit 1 04 and kit 1 76 from the
median of the total collective during the period of the
investigation (two medians are not shown, because
their values lay outside the presentation area). In most
cases, the medians of kit 1 04 and kit 1 76 differed
by between 30 and 40%. Relatively large differences
between the medians of individual subcollectives are
also shown in figures 5a and 5b for the determination
of oc-fetoprotein.
Several reasons may be considered for the sometimes
pronounced dependency of analytical results on the
kit used. In addition to the antigen heterogeneity of
native tumour markers (4), the multiplicity of com-
mercial antibodies, some of them raised against dif-
ferent epitopes of the antigen, inevitably leads to
differences in the composition of the kits. These dif-
ferences probably make a considerable contribution
to the observed kit-dependency of the results. The
comparability of analytical results from different lab-
oratories is severely limited by this marked method-
dependency, so that a correct interpretation of ana-
lytical values is possible only for one particular ana-
lytical procedure using one type of kit.
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Fig. 5. a) Relative differences between the medians of the re-
sults for α-fetoprotein obtained with kit 1 76 (^) or kit
2 04 (o) and the corresponding medians of the total
collectives.
b) Relative differences for kit 1 04 (o) and kit 1 08 (^).
Intel-laboratory surveys (6 samples per year) conducted
from 1986 to 1991.
4). From 1986 to 1988, the medians of the ot-fetopro-
tein determination with kit 1 76 showed relatively
large differences, whereas the differences in subse-
quent years were very small (fig. 5a). The results from
kit 1 08 remained constant with respect to the total
collective until 1988, but then displayed varying dif-
ferences, which since 1991 have been mostly positive
compared with the total collective (fig. 5b). These
phenomena suggest that changes have occurred in kit
quality. Such changes would not be in the interests of
patient care.
Dependency of results on the date
of the interlaboratory survey
Figures 4 and 5 show that kit-dependent differences
were not constant during the period of the interlab-
oratory surveys. Thus, in the analysis of carcinoem-
bryonic antigen during 1988 and 1989 there was a
marked decrease in the differences between the me-
dians of kit 1 76 and those of the total collective (fig.
Repeated determinations
in individual laboratories
The differences discussed so far between the interlab-
oratory survey results for a given analysed material
are largely the differences between the medians of
individual collectives of results. The predictive value
of such differences may be limited for the following
reasons.
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- The analysed material changes between interlab-
oratory surveys, and resulting changes in the ma-
trix of the samples could be a cause of inconsis-
tencies in the observed differences.
— The composition of the participating collective is
not constant, because not every laboratory takes
part in every interlaboratory survey. Especially in
the case of small collectives, the possibility cannot
be excluded that this influences the position of the
median.
Sometimes the same sample material was used in
different interlaboratory surveys. In these cases, the
sample matrix was not a variable, and therefore could
not have been responsible for the change in position
of the medians of the collectives. Some results of such
repeated determinations are shown in table 2. In ad-
dition, in order to eliminate the influence of the var-
iable composition of the collectives, a further study
was made of results obtained with the same kit in the
same laboratory for the analysis of samples of the
same material in different interlaboratory surveys.
Examples of these results are detailed in figure 6 for
the analytical quantity, α-fetoprotein. Although the
number of cases eligible for inclusion in this study is
relatively small, the figure clearly shows that all users
of kit 1 08, who participated in both interlaboratory
surveys, obtained markedly higher values in June 1991
than in November 1988 for the same sample material.
Moreover, the results from kit 2 04 were very non-
Tab. 2. Medians of the results for the determination of oc-fetoprotein (a) and carcinoembryonic antigen (b) in the same sample
material in two interlaboratory surveys. Three surveys were based on previously used sample material, the corresponding
first and second surveys being separated by different time intervals.
1) For all participating laboratories that used the same kit.
2) For those laboratories in 1) that participated in both surveys.
(Med = median, n = number of laboratories, D = difference between the medians of the first and second determination)
AFP* (kU/1) Repetition interval
Kit Coil. 3 Years 1 Year 4 Months
108
204
228
1 76
D
2)
D
2)
D
2)
1)
2)
Oct88
Med (n)
49.1 (17)
51
37.3 (20)
38.3
51.4(11)
51.4
41.7(14)
42.7
June 91
Med (n)
63.7 (14)
64.8 (7)
41.9(44)
39.4(10)
44.1 (29)
48.8 (7)
39 (24)
39.9 (7)
D
-h 14.6
4-13.8
+4.6
+ 1.1
-7.3
-2.6
-2.7
-2.8
Jan 90
Med (n)
12.2(18)
12.6
10.1 (22)
9.9
11.3(20)
11.1
10.9(17)
11.3
Jan 91
Med (n)
19.9(16)
19.8 (10)
10.7(43)
11 (18)
11 (33)
11.6(15)
9.8 (22)
10.4 (8)
D
+ 7.7
+ 7.2
+0.6
+ 1.1
-0.3
+ 0.5
-1.1
-0.9
June 89
Med (n)
3.3 (17)
4.4
6.1 (21)
6.2
5.5(16)
5.6
5.8(18)
5.9
Nov 89
Med (n)
3.8 (14)
3.5(12)
6.2 (20)
6.2(16)
5.9(18)
5.9(13)
5.9(16)
5.8(10)
D
+ 0.5
-0,9
+0,1
0
+0,4
+ 0,3
+ 0,1
-0,1
CEA** (μ§/1) Repetition interval
Kit Coll. 3 Years 1 Year 4 Months
1 04
1 20
• 1 30
204
274
D
2)
D
2)
D
2)
D
2)
D
2)
Oct 88
Med (n)
36.6(31)
36.8
29.4(15)
21.4 (9)
35.6 (37)
36.7
28.8(14)
June 91
Med (n)
34.3 (26)
35.3(16)
26.9 (23)
(4)
14.8(19)
(3)
28.3 (47)
31 (13)
42.3(18)
(3)
D
-2.3
-1.5
-2.5
-6.6
-7.3
-5.7
+ 13.5
Jan 90
Med (n)
23.8 (33)
24.3
22.1 (13)
22.1
25.2(17)
25.4
22.4 (32)
22
33.9(17)
31.9
Jan 91
Med (n)
22,9 (29)
23 (23)
20.9 (26)
20.3 (10)
28 (23)
29 (11)
18.6(50)
18.9(22)
36.7(18)
36.8 (8)
D
-0.9
-1.3
-1.2
-1.8
+ 2.8
+ 3.6
-3.8
-3.1
+2.8
+4.9
June 89
Med (n)
16.3 (36)
16.5
15.5(18)
15.5
18.4(16)
18.3
16 (32)
15
18.3(21)
18.2 ί
Nov 89
Med (n)
15.9(26)
16 (25)
15.1 (17)
15.2(12)
,14.6(14)
14.1 (11)
16 (27)
14.5 (17)
18.3(15)
19 (15)
D
-0.4
-0.5
-0.4
-0.3
-3.8
-4.2
0
-Ό.5
0
+0.8
* α-Fetoprotein
** Carcinoembryonic antigen
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uniform, but taken as a whole they do not suggest
that the analytical properties of the kits changes be-
tween the first and second investigation. The changes
in group 2 28 were less glaring than those in 1 08,
but the tendency to lower values in the second deter-
mination cannot be overlooked.
To reproduce the contents of figure 6 in abridged
from, the median of each first determination and the
corresponding second determination were listed in
table 2. With kit 1 08, the median of the second
determination (65 kU/1) was 27% higher than that of
the first determination (51 kU/1). Following the same
procedure, data were listed from two further repeated
determinations of -fetoprotein (tab. 2), and from
three repeated determinations of carcinoembryonic
antigen (tab. 2b). As mentioned above, tables 2a and
2b also contain the medians for the first and second
determinations of the complete subcollectives. Since
they originated at least partly from different labora-
tories, many results in these complete subcollectives
were not true repeated determinations. In most cases,
however, their medians largely corresponded to those
of the smaller groups of selected laboratories. At least
when the medians of the first and second determina-
tions differed by 20% and more, such differences can
hardly be explained by random effects or peculiarities
of the sample matrix. It is possible that, unknown to
the user, the analytical method had been changed.
Such changes would probably affect the reliability of
the test as a diagnostic tool.
70
=- 60
i-50
I 40
f 3 0
LL
8 20
10
0 1 08
1. 2.
1 76
1. 2.
204
1. 2.
228
1. 2.
Kit
Measurement
Fig. 6. Individual values from laboratories that used the same
kit in two interlaboratory surveys (Oct. 1988 and June
1991), in which the same control material was analysed.
The results of the first and second determination ( )
are joined by a line (· — o).
The precision of the determinations is particularly
crucial in follow-up studies of tumour patients, in
which laboratory tests are separated by relatively long
periods. Also, the "triple diagnostic", developed in
recent years for the calculation of Down syndrome
risk factors (5), uses the quantities oestradiol, a-fe-
toprotein and human chorionic gonadotropin, and
bases its predictive value (which is not undisputed)
on a very good repeatability of results (6). It is there-
fore important that kits and the quality of their per-
formance remain unchanged.
Conclusion
The examples presented here of interlaboratory sur-
veys of tumour markers show once again that ana-
lytical results can differ to a greater or lesser extent
from one another, depending on the reagent combi-
nations used for the analyses. In view of the com-
plexity of the analytical procedures, this is a plausible
state of affairs, and it has been repeatedly reported
and expounded (2, 7 — 11). Nevertheless, there are
grounds for believing that analysts and physicians are
not yet sufficiently aware of its implications. This
awareness is important, because the situation cannot
be expected to improve in the foreseeable future.
The situation will also not be changed by the fact
that international standard preparations are available
for some tumour markers. The heterogeneity of the
antigens, the multiplicity of antibodies and differences
in the methodology of kits will probably continue to
stand in the way of the desired harmonization of
analytical results from different laboratories. For the
time being, it will be necessary to accept a variable
degree of kit dependency in the results for tumour
markers. In the interests of diagnosis, it is therefore
all the more important to guarantee the reproduci-
bility of the results at least within each laboratory.
However, as shown by the data for repeated deter-
minations, this requirement was not always satisfied.
For the continuous monitoring of the constancy of
an analytical system, however, the conduct of inter-
laboratory surveys at relatively large time intervals is
of only limited value. Rapid and reliable information
on the repeatability of an analytical method can only
be obtained by strict internal laboratory control of
precision.
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